Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomes

References

• Almeida B, Nag OK, Rogers KE, Delehanty JB. 2020. Recent progress in bioconjugation strategies for liposome-mediated drug delivery. Molecules. 25(23):5672. doi: 10.3390/molecules25235672.
   PubMed Web of Science ®Google Scholar
• Amarante-Mendes GP, Griffith TS. 2015. Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther. 155:117–131. doi: 10.1016/j.pharmthera.2015.09.001.
   PubMed Web of Science ®Google Scholar
• Atari-Hajipirloo S, Nikanfar S, Heydari A, Kheradmand F. 2017. Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells. Res Pharm Sci. 12(1):67–73. doi: 10.4103/1735-5362.199049.
   PubMed Web of Science ®Google Scholar
• Atari-Hajipirloo S, Nikanfar S, Heydari A, Noori F, Kheradmand F. 2016. The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: involvement of COX-2, Caspase-3, VEGF and NF-κB genes expression. Cell Mol Biol (Noisy-le-Grand). 62(2):68–74.
   PubMed Web of Science ®Google Scholar
• Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, André T, Mareel M, et al. 2002. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res. 62(17):4879–4883.
   PubMed Web of Science ®Google Scholar
• Chang R, Fu R, Huang Y, Zhang J, Feng C, Wang R, Yan H, Li G, Chu X, Yuan F, et al. 2023. Codelivery of TRAIL and mitomycin C via liposomes shows improved antitumor effect on TRAIL-resistant tumors. Mol Pharm. 20(6):2864–2875. doi: 10.1021/acs.molpharmaceut.2c01013.
   PubMedGoogle Scholar
• Deng D, Shah K. 2020. TRAIL of hope meeting resistance in cancer. Trends Cancer. 6(12):989–1001. doi: 10.1016/j.trecan.2020.06.006.
   PubMed Web of Science ®Google Scholar
• Derakhshan A, Chen Z, Van Waes C. 2017. Therapeutic small molecules target inhibitor of apoptosis proteins in cancers with deregulation of extrinsic and intrinsic cell death pathways. Clin Cancer Res. 23(6):1379–1387. doi: 10.1158/1078-0432.CCR-16-2172.
   PubMed Web of Science ®Google Scholar
• Dhiman DK, Sanyal SN, Vaish V. 2020. Imatinib exhibit synergistic pleiotropy in the prevention of colorectal cancer by suppressing proinflammatory, cell survival and angiogenic signaling. Cell Signal. 76:109803. doi: 10.1016/j.cellsig.2020.109803.
   PubMed Web of Science ®Google Scholar
• Dianat-Moghadam H, Heidarifard M, Mahari A, Shahgolzari M, Keshavarz M, Nouri M, Amoozgar Z. 2020. TRAIL in oncology: from recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. Pharmacol Res. 155:104716. doi: 10.1016/j.phrs.2020.104716.
   PubMed Web of Science ®Google Scholar
• Du G, Sun X. 2023. Ethanol injection method for liposome preparation. Methods Mol Biol. 2622:65–70. doi: 10.1007/978-1-0716-2954-3_5.
   PubMedGoogle Scholar
• Gileadi O. 2017. Recombinant protein expression in E. coli: a historical perspective. Methods Mol Biol. 1586:3–10.
   PubMedGoogle Scholar
• Gong H, Cheng W, Wang Y. 2019. Tumor necrosis factor-related apoptosis-inducing ligand inhibits the growth and aggressiveness of colon carcinoma via the exogenous apoptosis signaling pathway. Exp Ther Med. 17(1):41–50.
   PubMed Web of Science ®Google Scholar
• Hamaï A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, et al. 2006. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation. Oncogene. 25(58):7618–7634. doi: 10.1038/sj.onc.1209738.
   PubMed Web of Science ®Google Scholar
• Han JM, Yee J, Cho YS, Gwak HS. 2020. Factors influencing imatinib-induced hepatotoxicity. Cancer Res Treat. 52(1):181–188. doi: 10.4143/crt.2019.131.
   PubMed Web of Science ®Google Scholar
• Hu T, Li Z, Gao CY, Cho CH. 2016. Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol. 22(30):6876–6889. doi: 10.3748/wjg.v22.i30.6876.
   PubMed Web of Science ®Google Scholar
• Jia D, Yang H, Tao Z, Wan L, Cheng J, Lu X. 2016. Preparation and characterization of a novel variant of human tumor necrosis factor-related apoptosis-inducing ligand from the rhesus monkey, Macaca mulatta. Appl Microbiol Biotechnol. 100(7):3035–3047. doi: 10.1007/s00253-015-7143-7.
   PubMed Web of Science ®Google Scholar
• Kotlarz A, Przybyszewska M, Swoboda P, Neska J, Miłoszewska J, Grygorowicz MA, Kutner A, Markowicz S. 2019. Imatinib inhibits the regrowth of human colon cancer cells after treatment with 5-FU and cooperates with vitamin D analogue PRI-2191 in the downregulation of expression of stemness-related genes in 5-FU refractory cells. J Steroid Biochem Mol Biol. 189:48–62. doi: 10.1016/j.jsbmb.2019.02.003.
   PubMed Web of Science ®Google Scholar
• Liu H, Su D, Zhang J, Ge S, Li Y, Wang F, Gravel M, Roulston A, Song Q, Xu W, et al. 2017. Improvement of pharmacokinetic profile of TRAIL via trimer-tag enhances its antitumor activity in vivo. Sci Rep. 7(1):8953. doi: 10.1038/s41598-017-09518-1.
   PubMedGoogle Scholar
• Moradpour Z, Barghi L. 2019. Novel approaches for efficient delivery of tyrosine kinase inhibitors. J Pharm Pharm Sci. 22(1):37–48. doi: 10.18433/jpps29891.
   PubMedGoogle Scholar
• Pimentel JM, Zhou JY, Wu GS. 2023. The role of TRAIL in apoptosis and immunosurveillance in cancer. Cancers (Basel). 15(10):2752. doi: 10.3390/cancers15102752.
   PubMed Web of Science ®Google Scholar
• Razeghian E, Suksatan W, Sulaiman Rahman H, Bokov DO, Abdelbasset WK, Hassanzadeh A, Marofi F, Yazdanifar M, Jarahian M. 2021. Harnessing TRAIL-induced apoptosis pathway for cancer immunotherapy and associated challenges. Front Immunol. 12:699746. doi: 10.3389/fimmu.2021.699746.
   PubMed Web of Science ®Google Scholar
• Russo E, Spallarossa A, Tasso B, Villa C, Brullo C. 2021. Nanotechnology of tyrosine kinase inhibitors in cancer therapy: a perspective. Int J Mol Sci. 22(12):6538. doi: 10.3390/ijms22126538.
   PubMed Web of Science ®Google Scholar
• Singh D, Tewari M, Singh S, Narayan G. 2021. Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy. Future Oncol. 17(5):581–596. doi: 10.2217/fon-2020-0727.
   PubMed Web of Science ®Google Scholar
• Smith LJ, Kukanich BK, Krugner-Higby LA, Schmidt BH, Heath TD. 2013. Pharmacokinetics of ammonium sulfate gradient loaded liposome-encapsulated oxymorphone and hydromorphone in healthy dogs. Vet Anaesth Analg. 40(5):537–545. doi: 10.1111/vaa.12042.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–249. doi: 10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Suski JM, Braun M, Strmiska V, Sicinski P. 2021. Targeting cell-cycle machinery in cancer. Cancer Cell. 39(6):759–778. doi: 10.1016/j.ccell.2021.03.010.
   PubMed Web of Science ®Google Scholar
• Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, et al. 2005. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer. 92(10):1881–1891. doi: 10.1038/sj.bjc.6602592.
   PubMed Web of Science ®Google Scholar
• Vallo S, Stege H, Berg M, Michaelis M, Winkelmann R, Rothweiler F, Cinatl J. Jr. 2020. Tumor necrosis factor‑related apoptosis‑inducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against first‑line chemotherapy. Oncol Rep. 43(4):1331–1337. doi: 10.3892/or.2020.7487.
   PubMed Web of Science ®Google Scholar
• Wang J, Gong JB, Wei ZP. 2021. Strategies for liposome drug delivery systems to improve tumor treatment efficacy. AAPS Pharm SciTech. 23(1):27.
   PubMed Web of Science ®Google Scholar
• Wang Y, Mandal D, Wang S, Kleinerman ES, Pollock RE, Lev D, Hayes-Jordan A. 2010. Platelet-derived growth factor receptor beta inhibition increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitivity: imatinib and TRAIL dual therapy. Cancer. 116(16):3892–3902. doi: 10.1002/cncr.25107.
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Marshall JL. 2019. Colon cancer in young adults: trends and their implications. Curr Oncol Rep. 21(1):3. doi: 10.1007/s11912-019-0756-8.
   PubMed Web of Science ®Google Scholar
• Yan W, Leung SS, To KK. 2020. Updates on the use of liposomes for active tumor targeting in cancer therapy. Nanomedicine (Lond). 15(3):303–318. doi: 10.2217/nnm-2019-0308.
   PubMed Web of Science ®Google Scholar
• Yan J, Wang L, Wang Z, Wang Z, Wang B, Zhu R, Bi J, Wu J, Zhang H, Wu H, et al. 2016. Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity. Cell Death Dis. 7(6):e2274–e2274. doi: 10.1038/cddis.2016.177.
   PubMedGoogle Scholar
• Yin Y, Yuan X, Gao H, Yang Q. 2020. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy. Int J Pharm. 573:118785. doi: 10.1016/j.ijpharm.2019.118785.
   PubMedGoogle Scholar
• Zhu H, Zhao F, Yu S, He J, Deng L, Yi C, Huang Y. 2012. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo. Int J Mol Med. 30(5):1087–1094. doi: 10.3892/ijmm.2012.1105.
   PubMed Web of Science ®Google Scholar